Chapter 7 : Community-Acquired Pneumonia in Human Immunodeficiency Virus-Infected Patients: Comparative Study of S and LSerogroup 1

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Community-Acquired Pneumonia in Human Immunodeficiency Virus-Infected Patients: Comparative Study of S and LSerogroup 1, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815660/9781555813901_Chap07-1.gif /docserver/preview/fulltext/10.1128/9781555815660/9781555813901_Chap07-2.gif


Bacterial pneumonia continues to be the most frequent pulmonary complication in human immunodeficiency virus (HIV)-infected patients, although its prevalence has decreased with the use of highly active antiretroviral therapy. The most common etiologic agent of community-acquired pneumonia (CAP) in infected and uninfected patients is . is at present one of the leading causes of CAP in the general population. This chapter compares the epidemiological data, clinical features, outcome, and mortality of pneumonia by and by spp. in HIV-infected patients. An observational, comparative study was performed in 15 HIV patients with CAP by (group 1) and 46 by (group 2). No statistically significant differences were observed between the two groups in either the use of an appropriate antibiotic treatment in the emergency department or in the delay from the presentation of the symptoms until the initiation of an appropriate antibiotic therapy. pneumonia (LP) should be considered as an opportunistic infection in HIV-infected patients, and the urinary antigen test should be mandatory whenever we are faced with CAP in an HIV-positive patient.

Citation: Pedro-Botet M, Sopena N, García-Cruz A, Mateu L, Roure S, Dominguez M, Sanchez I, Rey-Joly C, Sabrià M. 2006. Community-Acquired Pneumonia in Human Immunodeficiency Virus-Infected Patients: Comparative Study of S and LSerogroup 1, p 30-32. In Cianciotto N, Kwaik Y, Edelstein P, Fields B, Geary D, Harrison T, Joseph C, Ratcliff R, Stout J, Swanson M (ed), . ASM Press, Washington, DC. doi: 10.1128/9781555815660.ch07

Key Concept Ranking

Highly Active Antiretroviral Therapy
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Casau, N. C. 2004. Low prevalence of Legionnaires’ disease in HIV-infected patients. AIDS Read. 14: 269.
2. Cunha, B. A. 1998. Clinical features of Legionnaires’ disease. Semin. Respir. Infect. 13: 116127.
3. De Gaetano Donati, K.,, M. Tumbarello,, E. Tacconelli,, S. Bertagnolio,, R. Rabagliati,, G. Scoppetuolo,, R. Citton,, M. Cataldo,, E. Rastrelli,, G. Fadda, and, R. Cauda. 2003. Impact of highly active antiretroviral therapy (HAART) on the incidence of bacterial infections in HIV-infected subjects. J. Chemother. 16: 6065.
4. Feikin, D.,, C. Feldman,, A. Schuchat, and, E. N. Janoff. 2004. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect. Dis. 4: 445455.
5. Feldman, C. 2005. Pneumonia associated with HIV infection. Curr. Opin. Infect. 18: 165170.
6. Mulazimoglu, L., and, V. L. Yu. 2001. Can Le-gionniares’ disease be diagnosed by clinical criteria? A critical review. Chest 120: 10491053.
7. Pedro-Botet, M. L.,, M. Sabriá,, N. Sopena,, M. García-Núñez,, M. J. Domínguez,, E. Rey-naga, and, C. Rey-Joly. 2003. Legionnaires’ disease and HIV infection. Chest 124: 543547.
8. Sopena, N.,, M. Sabriá,, M. L. Pedro-Botet,, J. M. Manterola,, L. Matas,, J. Dominguez,, J. M. Mòdol,, P. Tudela,, V. Ausina, and, M. Foz. 1999. Prospective study of community-acquired pneumonia of bacterial etiology in adults. Eur. J. Clin. Microbiol. Infect. Dis. 18: 852858.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error